share_log

Immuneering | 8-K: Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates - Enrollment progressing well across all arms in the IMM-1-104 Phase 2a Trial, with Initial Data from Multiple Arms Expected in 2H 2024 -

Immuneering | 8-K: Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates - Enrollment progressing well across all arms in the IMM-1-104 Phase 2a Trial, with Initial Data from Multiple Arms Expected in 2H 2024 -

Immuneering | 8-K:Immuneering公佈2024年第二季度財務業績並提供業務最新情況-IMM-1-104 2a期試驗所有部門的註冊進展良好,預計將在2024年下半年獲得來自多個組的初步數據-
美股sec公告 ·  08/06 16:16
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息